Signori et al. 1 have provided, although provoking, data in their recent article. Raloxifene may inhibit tumor growth in a number of other systemic malignancies besides breast carcinomas.
For instance, it attenuates tumor growth in prostatic malignancies. It mediates this effect by downregulating Bcl-2 levels. As a result, there is augmented G0/G1 phase arrest within the prostatic tumor.
2 Extracellular-signal-regulated kinases 1/2 phosphorylation is typically seen. At the same time, Par-4 levels are upregulated within the cancerous cells. Inhibition of c-myc accompanies the above changes. 3 Caspase-3 activity is also accentuated secondary to the administration of raloxifene. Caspase-8 and caspase-9 activation also occurs. These effects are time dependent. Raloxifene is also effective in accentuating bone mineral density in males with prostate cancers who are on gonadotropin-releasing hormone agonist therapy. 4 Similar benefit is seen in colorectal malignancies. For instance, raloxifene when administered to colorectal cancer cell lines significantly reduces tumor growth. Raloxifene when used in adjunction with estrogen receptor b (introduced via adeno-virus vectors) further decreases and attenuates colon cancer proliferation. 5 The formation of aberrant crypt foci is especially mitigated. 6 Thus by virtue of its antagonistic effects, raloxifene significantly attenuates tumor growth in colonic malignancies.
The above examples suggest that raloxifene may have significant antineoplastic effects in systemic tumors besides breast carcinomas.
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